-
-
Kost and colleagues provide updated contraceptive failure rates derived from the 2002 National Survey of Family Growth.
-
In this issue: Rosiglitazone (Avandia) implicated in yet another study; Prilosec and Nexium not associated with cardiac events; Anastrozole (Arimidex) shown more effective than tamoxifen for treatment of early-stage breast cancer; antibiotics show no effect on sinusitis; FDA actions.
-
Of note, this publication is a review article and not original science. The use of and possible indications for Computed Tomography (CT) scans have been rapidly growing since its introduction, particularly in the area of adult screening (ie, virtual colonoscopy, CT whole-body screening).
-
In this issue: FDA warnings for existing drugs dominate pharmaceutical news this month.
-
In the November 20th issue of the Journal of Clinical Oncology, two important articles appear, demonstrating the clinical impact of a novel therapeutic, bevacizumab, in women with recurrent ovarian cancer.
-
The Collaborative Group on Epidemiological Studies of Cervical Cancer has combined and reanalyzed any relevant data from all epidemiological studies on the association between cervical carcinoma and the pattern of oral contraceptive use.
-
-
Last month an article was featured in the OB/GYN Clinical Alert from the October issue of Obstetrics & Gynecology. Since the issue was rich in good material, I will go back to it to review information pertaining to one of the most common questions asked of providers"How much weight should I gain in my pregnancy?"
-
Human Papillomavirus (HPV) testing has proved efficacious in triaging minimally abnormal cytology to further investigation or surveillance. However, despite its high sensitivity for cervix pathology, its value as a primary screening technology has been formally evaluated in only a limited way.